vs
Side-by-side financial comparison of PureTech Health plc (PRTC) and AVITA Medical, Inc. (RCEL), based on the latest 10-Q / 10-K filings. Click either name above to swap in a different company.
PureTech Health is an American biotechnology company which develops medicines to combat serious diseases. It is listed on the London Stock Exchange.
Avita Medical is a clinical and commercial company developing and marketing a range regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in Europe, the Middle East...
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history — bar widths are scaled to the larger of the two companies so you can eyeball the size gap and growth trajectory without doing math. Quarters aligned by calendar period (report date) so offset fiscal years line up.
| Q4 25 | — | $17.6M | ||
| Q3 25 | — | $17.1M | ||
| Q2 25 | — | $18.4M | ||
| Q1 25 | — | $18.5M | ||
| Q4 24 | — | $18.4M | ||
| Q3 24 | — | $19.5M | ||
| Q2 24 | — | $15.2M | ||
| Q1 24 | — | $11.1M |
| Q4 25 | — | $-11.6M | ||
| Q3 25 | — | $-13.2M | ||
| Q2 25 | — | $-9.9M | ||
| Q1 25 | — | $-13.9M | ||
| Q4 24 | — | $-11.6M | ||
| Q3 24 | — | $-16.2M | ||
| Q2 24 | — | $-15.4M | ||
| Q1 24 | — | $-18.7M |
| Q4 25 | — | 81.2% | ||
| Q3 25 | — | 81.3% | ||
| Q2 25 | — | 81.2% | ||
| Q1 25 | — | 84.7% | ||
| Q4 24 | — | 87.6% | ||
| Q3 24 | — | 83.7% | ||
| Q2 24 | — | 86.1% | ||
| Q1 24 | — | 86.4% |
| Q4 25 | — | -59.1% | ||
| Q3 25 | — | -53.6% | ||
| Q2 25 | — | -60.5% | ||
| Q1 25 | — | -63.9% | ||
| Q4 24 | — | -54.1% | ||
| Q3 24 | — | -70.6% | ||
| Q2 24 | — | -102.8% | ||
| Q1 24 | — | -155.0% |
| Q4 25 | — | -66.0% | ||
| Q3 25 | — | -77.3% | ||
| Q2 25 | — | -53.9% | ||
| Q1 25 | — | -74.9% | ||
| Q4 24 | — | -63.0% | ||
| Q3 24 | — | -82.9% | ||
| Q2 24 | — | -101.3% | ||
| Q1 24 | — | -168.0% |
| Q4 25 | — | $-0.37 | ||
| Q3 25 | — | $-0.46 | ||
| Q2 25 | — | $-0.38 | ||
| Q1 25 | — | $-0.53 | ||
| Q4 24 | — | $-0.44 | ||
| Q3 24 | — | $-0.62 | ||
| Q2 24 | — | $-0.60 | ||
| Q1 24 | — | $-0.73 |
Financial Flow Comparison
Sankey diagram of revenue → gross profit → operating profit → net profit for each company. Charts shown full-width and stacked so both segment hierarchies are readable side-by-side on desktop and mobile.
